Neximmune Inc Quick Ratio (NEXI) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Neximmune Inc   (NEXI)

Neximmune Inc 's Quick Ratio

NEXI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2024, Quick Ratio fell to 0.51 a new company low.

Within Major Pharmaceutical Preparations industry 447 other companies have achieved higher Quick Ratio than Neximmune Inc in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 1133 to 3051.

Explain Quick Ratio?
How much Cash & cash equivalents NEXI´s has?
What are NEXI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NEXI Quick Ratio (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change -24.43 % -31.71 % -51.46 % -33.95 % -31.23 %
Y / Y Cash & cash equivalent Change -85.11 % -80.05 % -90.76 % -80.37 % -69.36 %
Quick Ratio MRQ 0.51 0.96 0.64 1.45 2.6
NEXI's Total Ranking # 3051 # 1133 # 1593 # 1431 # 1011
Seq. Current Liabilities Change 2.21 % -7.6 % -19.17 % -1 % -7.64 %
Seq. Cash & cash equivalent Change -45.56 % 39.05 % -64.42 % -44.72 % -27.04 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 448
Healthcare Sector # 842
Overall Market # 3051


Quick Ratio Statistics
High Average Low
74.71 10.57 0.51
(Dec 31 2021)   (Jun 30 2024)




Financial Statements
Neximmune Inc 's Current Liabilities $ 5 Millions Visit NEXI's Balance sheet
Neximmune Inc 's Cash & cash equivalent $ 2 Millions Visit NEXI's Balance sheet
Source of NEXI's Sales Visit NEXI's Sales by Geography


Cumulative Neximmune Inc 's Quick Ratio

NEXI's Quick Ratio for the trailling 12 Months

NEXI Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -37.19 % -37.91 % -32.45 % 10.85 % 32.54 %
Y / Y Cash & cash equivalent TTM Growth -83.98 % -78.88 % -74.43 % -66.54 % -59.38 %
Quick Ratio TTM 0.93 1.49 2.09 2.78 3.63
Total Ranking TTM # 3541 # 2473 # 3430 # 2473 # 3321
Seq. Current Liabilities TTM Growth -6.92 % -8.87 % -17.97 % -9.73 % -7.99 %
Seq. Cash & cash equivalent TTM Growth -42.07 % -35.16 % -38.23 % -30.95 % -23.63 %

Quick ratio ranking by company, industry and sector >> Back to NEXI Financial Strength Comparisons >> Go to Compare NEXI Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in NEXI's Current Liabilities to $4.74 millions, cumulative Quick Ratio to 0.93 below the NEXI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 453 other companies have achieved higher Quick Ratio than Neximmune Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 2473 to 3541.

Explain Quick Ratio?
How much Cash & cash equivalents NEXI´s has?
What are NEXI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 454
Healthcare Sector # 950
Within the Market # 3541


trailing twelve months Quick Ratio Statistics
High Average Low
15.1 5.95 0.92
(Dec 31 2021)   (Jun 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Ainos Inc   1.40 $ 8.014  Millions$ 5.743  Millions
Spero Therapeutics Inc   1.39 $ 63.527  Millions$ 45.633  Millions
Notable Labs Ltd   1.39 $ 4.092  Millions$ 2.948  Millions
Kamada Ltd   1.38 $ 56.547  Millions$ 40.896  Millions
Protagenic Therapeutics Inc new  1.37 $ 0.925  Millions$ 0.675  Millions
Bio path Holdings inc   1.36 $ 4.006  Millions$ 2.955  Millions
Beone Medicines Ltd   1.34 $ 2,592.655  Millions$ 1,938.768  Millions
Harrow Inc   1.33 $ 70.968  Millions$ 53.551  Millions
Nucana Plc  1.31 $ 14.203  Millions$ 10.851  Millions
Telix Pharmaceuticals Ltd  1.30 $ 719.860  Millions$ 552.751  Millions
Zymeworks Inc   1.30 $ 70.963  Millions$ 54.713  Millions
Molecular Templates Inc   1.26 $ 9.657  Millions$ 7.680  Millions
Tff Pharmaceuticals Inc  1.21 $ 4.387  Millions$ 3.618  Millions
Procyon Corporation  1.18 $ 0.909  Millions$ 0.769  Millions
Annovis Bio Inc   1.18 $ 3.998  Millions$ 3.395  Millions
Imunon Inc   1.16 $ 5.307  Millions$ 4.561  Millions
Biomarin Pharmaceutical Inc  1.15 $ 1,224.351  Millions$ 1,067.337  Millions
Sonnet Biotherapeutics Holdings Inc   1.14 $ 3.554  Millions$ 3.110  Millions
Dar Bioscience Inc   1.13 $ 16.415  Millions$ 14.590  Millions
Bgm Group Ltd  1.12 $ 9.817  Millions$ 8.776  Millions
23andme Holding Co  1.11 $ 169.971  Millions$ 152.857  Millions
Genprex Inc   1.09 $ 2.459  Millions$ 2.259  Millions
Revelation Biosciences Inc   1.08 $ 12.073  Millions$ 11.129  Millions
Amphastar Pharmaceuticals Inc   1.08 $ 251.676  Millions$ 232.412  Millions
Esperion Therapeutics Inc   1.08 $ 189.304  Millions$ 175.338  Millions
Organigram Global Inc   1.08 $ 81.767  Millions$ 75.747  Millions
Nature s Sunshine Products inc   1.08 $ 68.695  Millions$ 63.649  Millions
Transcode Therapeutics Inc   1.06 $ 3.466  Millions$ 3.275  Millions
Viracta Therapeutics Inc   1.05 $ 30.005  Millions$ 28.578  Millions
Organogenesis Holdings Inc   1.05 $ 89.902  Millions$ 85.727  Millions

Date modified: 2026-10-07T00:41:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.